GLS activity corresponds with poor clinical prognosis in patients with breast, colorectal, lung, liver, and brain tumors, and rapid-growing tumor cells have enhanced GLS mRNA levels as well as elevated GLS expression [4,6,7,8,9]. The gene discussed is GLS; the disease is neoplasm.